Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure

Journal of Clinical Apheresis

Volumn 32, Issue 4, 2017, Pages 224-234

  Worel, Nina ^a   Fritsch, Gerhard ^b   Agis, Hermine ^a   Böhm, Alexandra ^c   Engelich, Georg ^d   Leitner, Gerda C ^a   Geissler, Klaus ^e   Gleixner, Karoline ^a   Kalhs, Peter ^a   Buxhofer Ausch, Veronika ^c   Keil, Felix ^f   Kopetzky, Gerhard ^g   Mayr, Viktor ^h   Rabitsch, Werner ^a   Reisner, Regina ^f   Rosskopf, Konrad ⁱ   Ruckser, Reinhard ^j   Zoghlami, Claudia ^e   Zojer, Niklas ^k   Greinix, Hildegard T ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d Wiener Neustadt Hospital   (Austria)

^e Neurological Center Rosenhuegel   (Austria)

^f HANUSCH HOSPITAL   (Austria)

^g General Hospital Southwest   (Austria)

^h Hospital Krems   (Austria)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j Division of Oncology   (Austria)

^k WILHELMINEN HOSPITAL   (Austria)

more..

Author keywords

binding inhibitor; poor stem cell mobilization; preemptive approach

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULOCYTE; HODGKIN DISEASE; HUMAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MULTIPLE MYELOMA; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NAUSEA; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; SIDE EFFECT; STEM CELL MOBILIZATION; TREATMENT FAILURE; AUTOGRAFT; AUTOTRANSPLANTATION; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PREMEDICATION; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; AUTOGRAFTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84992428142     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21496     Document Type: Article

References (46)

1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation 2010; 45:219–234.
2. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353–357.
3. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150:647–62.
4. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation 2009; 43:181–413–95.
5. Saraceni F, Shem-Tov N, Olivieri A, Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplantation 2015;50:886–891.
6. Sola C, Maroto P, Salazar R, Mesia R, Mendoza L, Brunet J, et al. Bone transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4:195–209.
7. Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E, et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-425 Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000; 36:2360–2367.
8. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120:413–423.
9. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547–2555.
10. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003; 29:29–37.
11. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22:1282–1284.
12. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by GM-CSF and G-CSF and requirement for endogenous M-CSF. J Leuk Biol 2000 Jul; 68:144–150.
13. Fu P, Bagai RK, Meyerson H, Kane D, Fox RM, Creger RJ, et al. Premobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant 2006;38:189–196.
14. Lefrere F, Zohar S, Beaudier S, Audat F, Ribeil JA, Ghez D, et al. Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion 2007; 47:1851–1857.
15. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14:1045–1056.
16. Jantunen E, Varmavuo V, Juutilainen A, Kuittinen T, Mahlamaki E, Mantymaa P, et al. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol 2012; 91:1073–1079.
17. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46:356–363.
18. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41:331–338.
19. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767–4773.
20. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720–5726.
21. Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on-demand” scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion 2015; 55:2149–2157.
22. Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, et al. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion 2015; 55:275–283.
23. Sanchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant 2015;50:34–39.
24. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47:342–351.
25. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23 Suppl 2:S29–S33.
26. Gorgens A, Ludwig AK, Mollmann M, Krawczyk A, Durig J, Hanenberg H, et al. Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages. Stem Cell Rep 2014; 3:1058–1072.
27. Gorgens A, Radtke S, Horn PA, Giebel B. New relationships of human hematopoietic lineages facilitate detection of multipotent hematopoietic stem and progenitor cells. Cell Cycle 2013; 12:3478–3482.
28. Dmytrus J, Matthes-Martin S, Pichler H, Worel N Geyeregger R, et al. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant 2016;51:1093–1100.
29. Hosing C, Saliba RM, Ahlawat S, Korbling M, Kebriaei P, Alousi A, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84:335–337.
30. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37:719–724.
31. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16:490–499.
32. Basquiera AL, Abichain P, Damonte JC, Ricchi B, Sturich AG, Palazzo ED, et al. The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation. J Clin Apher 2006; 21:92–95.
33. Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43:495–501.
34. Armitage S, Hargreaves R, Samson 5D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997; 20:587–591.
35. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011; 90:557–568.
36. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46:1045–1052.
37. Worel N, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, et al. European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. Transfusion 2012; 52:2395–2400.
38. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51:968–975.
39. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18:241–249.
40. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondnon G, et al. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 2013 Sep; 88:754–757.
41. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51:2175–2182.
42. Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012; 47:1403–1408.
43. Görgens A, Murke F, Kordelas L, Giebel B. Lost in Transplantation? Unexpected shift from multipotent to late lymphomyeloid hematopoietic stem and progenitor cells in patients 1 year after hematopoietic stem cell transplantation. Bone Marrow transplantation 2016;51:1073–1075.
44. Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Saily M, Sankelo M, et al. Blood graft cellular composition and early post-transplant recovery in myeloma patients mobilized with or without low-dose cyclophosphamide—a randomized comparison. Bone Marrow Transplant 2015; 50:S18–S.
45. Varmavuo V, Mantymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012; 89:128–135.
46. Varmavuo V, Mantymaa P, Silvennoinen R, Nousiainen T, Kuittinen T, Jantunen E. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 2013; 53:1024–1032.